Laxxon Medical to Participate in the World Orphan Drug Congress USA 2024

   Laxxon Medical to Participate in the World Orphan Drug Congress
   USA 2024
   New York, 04/23/2024 / 16:40, EST/EDT - EQS Newswire - Laxxon
   Medical

Laxxon Medical, a leading 3D screen printing platform technology company,
announced today its participation in the World Orphan Drug Congress USA
2024, taking place April 23-25, 2024 in Boston, Massachusetts.

Dr. Catherine Gatza, Vice President of Regulatory Affairs at Laxxon Medical,
will represent the Company at the World Orphan Drug Congress USA. The World
Orphan Drug Congress is a defining event for the global rare disease and
orphan drug space, bringing together leading pharmaceutical and biotech
companies, government and regulatory authorities, patient advocacy groups,
payers, investors and solution providers. The conference is a place to meet
and brainstorm ways to advance orphan drug development and improve access to
life-saving therapies.

About Laxxon Medical

Laxxon Medical is a leading pharma-technology company pioneering a new
generation of advanced pharmaceuticals through SPID�-Technology, a 3D screen
printing platform technology which unlocks innovative drug delivery
advancements paired with fast-tracked market access and extensive IP
protection to yield disruptive opportunities for the pharmaceutical industry
and its patients.

With SPID�, Laxxon can develop and manufacture advanced versions of new and
existing pharmaceutical drugs while extending and adding new patent
protection through the technology transfer process. Laxxon can fully utilize
the FDA's 505b(2) regulatory pathway in the US and Hybrid applications under
article 10(3) of Directive 2001/83/EC in the EUR, which fast tracks product
routes to market, and Laxxon's robust and growing IP protects any Company
asset until at least 2037.

Laxxon's pipeline includes ongoing working-projects with notable pharma
players, biotech companies and research universities, in addition to 13
in-house Advanced Patented Generics products. Laxxon's IP is continuously
growing and consists of 150 patents and patent applications with more than
3,000 patent claims.

Company website: www.laxxonmedical.com.

Investor Contact:

Alexander Ruckdaeschel
Chief Strategy Director
alexander.ruckdaeschel@laxxonmedical.com

Media Contact:

Frances Hoggard
Communications Manager
frances.hoggard@laxxonmedical.com

SOURCE: Laxxon Medical


04/23/2024 EQS Newswire / EQS Group AG